A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs LY 3214996 (Primary) ; Abemaciclib; Gemcitabine; Midazolam; Paclitaxel
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 28 Mar 2018 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.
- 28 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jan 2020.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.